



Press release from Emotra AB (publ)  
Gothenburg December 27, 2013

## Emotra signs agreement with internationally leading scientist

**Emotra has signed an agreement with Professor Marco Sarchiapone, Medicine and health Science Department, University of Molise, Via De Santis, 86100 Campobasso, Italy. Professor Sarchiapone, who is worldwide recognized person within the suicide research will take a leading position in the coordination of the planned multi-center study and in organizing international scientific meetings about the new technique Emotra is working with, a technique which has the possibility to radically change how the psychiatric care is diagnosing risk patients for suicide.**

In specific, Professor Sarchiapone will be deeply involved in recruiting further clinical centers, in finalizing the study protocol, in the coordination of the study and in the organization of international symposia about the subject in conjunction with annual world congresses. Professor Sarchiapone has many years' experience of organizing and coordinating broad international research studies within the field of suicide prevention and today Sarchiapone is heading the important suicide section of EPA, the European Psychiatric Association.

- *That we now have Professor Sarchiapone onboard means a lot for the work ahead. Our strategy is to get the method accepted by the leading clinicians in the field and now we have access to a world famous authority, who in his strong position can see to that the method will reach the market at major international meetings, says the president of Emotra, Claes Holmberg.*

In all, 15 leading European clinical teams should evaluate the use of EDOR, during the next two years. Discussions and negotiations are ongoing with several other groups from different countries. For the purpose of preparing these clinical studies, applications to ethical committees and preparations of CE-marking are ongoing parallel to this other work.

Emotra is at present in a very dynamic phase and its activities involve an increasing number of clinical centers. In order to minimize the financial risks, all work is done in a small organization and in such a cost effective manner as possible. When the support for EDOR from these clinical teams, is strong enough, the method will be launched in Europe.

*For more information, please contact*

*Claes Holmberg, President and CEO, Emotra AB, Telephone: +46708254547, [claes@emotra.se](mailto:claes@emotra.se)*

*or Lars-Håkan Thorell, Research Manager, Emotra AB, Telephone: +46733953120, [lars@emotra.se](mailto:lars@emotra.se)*

---

**Emotra AB** has developed a method –EDOR- with the purpose to evaluate the suicide risks of depressed patients. The method has in studies, involving more than 1000 patients demonstrated an accuracy of 97 percent. In other words, EDOR can, with 97 percent certainty conclude if a depressed patient has a significantly higher risk to commit suicide, and therefor needs suicide preventive actions. With EDOR it is possible to secure that relevant preventive actions will be offered to those patients who really need these.

Emotra AB (publ), Göteborgsvägen 74, 433 63 Sävedalen, Sweden

Telephone: +46 708 25 45 47, [www.emotra.se](http://www.emotra.se)